| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | éti-cel (UCART20x22) Non-Hodgkin lymphoma (NHL) | Phase 1 | — | Cell Therapies | Oncology | ||
phase 1 data readout example | éti-cel (UCART20x22) Non-Hodgkin lymphoma (NHL) | Phase 1 | — | Cell Therapies | Oncology | ||
phase 1 data readout example | éti-cel (UCART20x22) Non-Hodgkin lymphoma (NHL) | Phase 1 | — | Cell Therapies | Oncology |
Recent Updates
Recently added Catalysts
Cellectis S.A.$3.09
0 (0%)
D 33Pipeline Score Overvalued Biotech · Clinical
Market Cap
257.06 M
EPS
-0.67
P/E Ratio
-
Value Trade
319.47 K
-14.84 %
Week
-12.5 %
1 Month
-11.62 %
3 Month
-27.08 %
6 Month
-78.13 %
5 Year
-91.57 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
36.73 K
52 Week Range
1.33 - 5.48
% held by Insiders
3.93 %
% held by Institutions
14.2 %
Enterprise Value
180.00 M
Total Shares
72.33 M
Short %
0.51 %
Float Shares
69.48 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D33
Pipeline Score $40M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.2x
rNPV / MCap Top 39%
Micro Cap (rank 553 of 905)
Percentile RankCellectis S.A. faces pipeline headwinds (33/100), with $414M risk-adjusted pipeline value, led by UCART20x22 in B-cell Non-Hodgkin Lymphoma (B-NHL) (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UCART20x22 Monoclonal antibody | B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1 | NCT05607420 | 39% | $183M | RECRUITING | 80 | STALLED | D (36) | Aug 1, 2027 | ELEVATED_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
lasme-cel | relapsed/refractory B-cell acute lymphoblastic leukemia | Phase 1 | 2025-10-17 | |||
lasme-cel | relapsed/refractory B-cell acute lymphoblastic leukemia | Phase 1 | 2025-10-17 | |||
lasme-cel | relapsed/refractory B-cell acute lymphoblastic leukemia | Phase 1 | 2025-10-17 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CLLS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
CLLS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CLLS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CLLS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CLLS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CLLS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-06-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Cellectis S.A. (CLLS) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How CLLS ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Leukemia | #42 of 64 | UCART123v1.2 | AMGN LLY AZN | $4.28B | 0.75 | ||
| Lymphoma | #55 of 69 | UCART20x22 + CLLS52 | REGN LLY MRK | $8.52B | 0.69 |